Published in Am J Pathol on March 01, 1996
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med (1996) 2.75
Viruses and apoptosis. Int J Exp Pathol (2001) 1.03
T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol (1998) 0.93
Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues. Proc Natl Acad Sci U S A (1998) 0.93
Characterization of the interleukin-1beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol (1999) 0.90
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96
Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med (1989) 7.07
Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell (1990) 5.73
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 4.58
Expression and structure of the human NGF receptor. Cell (1986) 3.82
A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 3.62
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 3.21
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest (1993) 3.13
Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol (1992) 2.83
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood (1995) 2.57
Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol (1993) 2.50
Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol (1993) 2.45
DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol (1992) 2.37
Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood (1994) 1.94
Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer (1994) 1.87
The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol (1991) 1.60
APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol (1993) 1.39
Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet (1990) 1.31
Inverse expression of bcl-2 protein and Fas antigen in lymphoblasts in peripheral lymph nodes and activated peripheral blood T and B lymphocytes. Blood (1994) 1.24
Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood (1995) 1.11
Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma (1995) 1.10
The distribution of neoplastic and normal B-lymphoid cells in nodular lymphomas: use of an immunoperoxidase technique on frozen sections. Hum Pathol (1982) 1.08
Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood (1992) 1.05
The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics (1992) 0.97
Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol (1994) 0.94
Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer (1993) 0.92
Expression of the Fas antigen on primary human leukemia cells. Ann Hematol (1995) 0.78
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Comparative genomics of the eukaryotes. Science (2000) 26.62
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Genome annotation assessment in Drosophila melanogaster. Genome Res (2000) 11.77
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. Methods Enzymol (1990) 5.35
Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med (1979) 5.19
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol (1992) 4.04
A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature (1980) 3.90
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell (1985) 3.86
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol (1996) 2.68
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature (1985) 2.51
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
Diagnostic electron microscopy of faeces. II. Acute gastroenteritis associated with reovirus-like particles. J Clin Pathol (1974) 2.33
Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol (2001) 2.28
Life-styles, adaptive strategies, and sexual behaviors of homeless adolescents. Hosp Community Psychiatry (1993) 2.28
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med (1992) 2.26
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med (1989) 2.25
Viral genome organizer: a system for analyzing complete viral genomes. Virus Res (2000) 2.24
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Health status and access to health services among the urban homeless. Am J Public Health (1986) 2.15
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med (2000) 2.09
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet (1999) 2.08
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A (1991) 2.04
Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases. Am J Surg Pathol (1991) 2.00
Lymphomas of the breast: pathology and clinical behavior. Semin Oncol (1999) 2.00
Alternative birth positions. Can Fam Physician (1988) 1.97
Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature (1983) 1.93
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest (1981) 1.93
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92
Vi reaction in Hong Kong. Br Med J (1967) 1.85
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest (1997) 1.84
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science (1985) 1.83
CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature (1989) 1.82
Marginal zone B-cell lymphoma of the salivary gland arising in chronic sclerosing sialadenitis (Küttner tumor). Am J Surg Pathol (2001) 1.80
Familial backgrounds and risk behaviors of youth with thrownaway experiences. J Adolesc (1998) 1.78
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood (1981) 1.77
Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol (1993) 1.75
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
CD5+ extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol (1996) 1.72
Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst (1983) 1.72
Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol (2001) 1.68
Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology (1995) 1.68
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
A revised European-American classification of lymphoid neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol (1995) 1.67
Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A (1990) 1.66
Lymphoma of the kidney. A report of 11 cases. Am J Surg Pathol (1995) 1.65
A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med (1986) 1.63
Lymphoid infiltrates of the stomach. Evaluation of histologic criteria for the diagnosis of low-grade gastric lymphoma on endoscopic biopsy specimens. Am J Surg Pathol (1990) 1.63
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med (1983) 1.62
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol (1998) 1.61
Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood (2000) 1.60
Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature (1983) 1.58
Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol (1981) 1.57
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood (1981) 1.57
Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol (1982) 1.56
Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood (1998) 1.56
Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood (1983) 1.54
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood (1998) 1.52
Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer (1994) 1.52
Extranodal lymphoid infiltrates and mucosa-associated lymphoid tissue (MALT). A unifying concept. Am J Surg Pathol (1991) 1.51
Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol (1987) 1.50
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med (1999) 1.47
Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol (1996) 1.45
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.45
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol (1999) 1.45
Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei. Am J Clin Pathol (1990) 1.44
Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathologic study of 69 cases with immunophenotypic analysis. Am J Surg Pathol (1994) 1.42
Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood (2000) 1.42
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest (2000) 1.41
Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. Blood (1995) 1.41
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A (1988) 1.41
Myeloperoxidase detection by three-color flow cytometry and by enzyme cytochemistry in the classification of acute leukemia. Am J Clin Pathol (1998) 1.40
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood (1996) 1.40
Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype. Cancer (1990) 1.38
Standardization of the surgical pathology report. Mod Pathol (1992) 1.38
Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. A clinicopathologic analysis of 27 cases. Cancer (1984) 1.38
Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med (1985) 1.37
Breast lymphoma. A B-cell spectrum including the low grade B-cell lymphoma of mucosa associated lymphoid tissue. Am J Surg Pathol (1993) 1.37
Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol (1993) 1.36
Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res (1999) 1.34
Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases. Am J Surg Pathol (1989) 1.34
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood (1996) 1.33
Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med (1985) 1.32
Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A (1995) 1.32
Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis (2004) 1.31
P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. Br J Pharmacol (1998) 1.30
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol (1999) 1.29
Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues. Am J Pathol (1992) 1.29